Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose.

Sholukh, Anton M.
Byrareddy, Siddappa N.
Shanmuganathan, Vivekanandan.
Hemashettar, Girish.
Lakhashe, Samir K.
Rasmussen, Robert A.
Watkins, Jennifer D.
Vyas, Hemant K.
Thorat, Swati.
Brandstoetter, Tania.
Mukhtar, Muhammad M.
Yoon, John K.
Novembre, Francis J.
Villinger, Francois.
Landucci, Gary.
Forthal, Donald N.
Ratcliffe, Sarah.
Tuero, Iskra.
Robert-Guroff, Marjorie.
Polonis, Victoria R.
Bilska, Miroslawa.
Montefiori, David C.
Johnson, Welkin E.
Ertl, Hildegund C.
Ruprecht, Ruth M.
2014

Background: A key goal for HIV-1 envelope immunogen design is the induction of cross-reactive neutralizing antibodies (nAbs). As AIDS vaccine recipients will not be exposed to strains exactly matching any immunogens due to multiple HIV-1 quasispecies circulating in the human population worldwide, heterologous SHIV challenges are essential... read more

Permanent URL
http://hdl.handle.net/10427/010150
Original publication
Sholukh, Anton, Siddappa N. Byrareddy, Vivekanandan Shanmuganathan, Girish Hemashettar, Samir K. Lakhashe, Robert A. Rasmussen, Jennifer D. Watkins, Hemant K. Vyas, Swati Thorat, Tania Brandstoetter, Muhammad M. Mukhtar, John K. Yoon, Francis J. Novembre, Francois Villinger, Gary Landucci, Donald N. Forthal, Sarah Ratcliffe, Iskra Tuero, Marjorie Robert-Guroff, Victoria R. Polonis, Miroslawa Bilska, David C. Montefiori, Welkin E. Johnson, Hildegund C. Ertl, and Ruth M. Ruprecht. "Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose." Retrovirology 11, no. 1 (12, 2014): 1-15.
ID: tufts:17520
To Cite: DCA Citation Guide
Usage: Detailed Rights